In our study, an increasing trend in palivizumab coverage rates was observed as the seasons progressed, a trend also noted in other studies [ 18 , 19 ].
← all excerpts
Palivizumab coverage rates among moderate-to-late preterm infants in Korea: a nationwide cross-sectional study.
1
—
—